Iovance Biotherapeutics, Inc.
Clinical trials sponsored by Iovance Biotherapeutics, Inc., explained in plain language.
A biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Hacked immune cells take on tough cancers Results expected Sep 2027 (estimated)
-
Can your own immune cells fight advanced cancer?
Cure Not yet recruitingThis trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…
Phase 1/2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced sarcoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC